-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol Myers Squibb to Present Phase 3 Zenbexus Multiple Myeloma Data at ASH 2026

PUBT·11/19/2026 12:01:31
Diffusion vocale
Bristol Myers Squibb to Present Phase 3 Zenbexus Multiple Myeloma Data at ASH 2026
  • Bristol Myers Squibb will present hematology trial data at the ASH meeting in New Orleans, December 12-15, 2026.
  • Phase 3 EXCALIBER-RRMM results will assess disease progression and residual disease with a Zenbexus-based combination in relapsed or refractory multiple myeloma.
  • Five-year Phase 3 TRANSFORM follow-up will highlight Breyanzi's potential for cure in second-line relapsed or refractory large B-cell lymphoma.
  • Early-stage results will evaluate dual-targeted CAR T therapy tunlucabtagene autoleucel's safety and efficacy in relapsed or refractory multiple myeloma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261118967070) on November 19, 2026, and is solely responsible for the information contained therein.